Abstract：
Benzydamine hydrochloride is a locally-acting Non-Steroidal Anti-Inflammatory Drug (NSAID) with combined local anesthetic and analgesic properties, indicated for the symptomatic relief of pain in acute sore throat. The aim of this study was to obtain an European Consensus among pharmacists, general practitioners and pediatricians on the appropriate use of benzydamine hydrochloride in the treatment of sore throat.
The authors developed a Delphi questionnaire organized into 15 statements focused on 4 topics: the mechanism of action of benzydamine, the benzydamine treatment in an adult patient and in a pediatric patient, and the advantages of benzydamine over other topical treatments. The survey was administered to a panel of to 320 participants including general practitioners, pediatricians, and pharmacists from 6 European countries (Italy, Germany, Portugal, Romania, Russia, and Spain), who rated their level of agreement or disagreement with each statement on a 6-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with each statement.
Panelists\' agreement on statements was very high. Consensus was reached for all 15 statements in the Delphi survey, with more than 98% positive agreement on topic 4, suggesting a shared view among European healthcare professionals (HCPs) about the advantages of benzydamine over other topical treatments. A strong consensus (> 99%) was reached for all the statements of topic 1 regarding the mechanism of action of benzydamine, except for its anesthetic properties (79%). Strong agreement was reached for all statements in topics 2 and 3 regarding the treatment of acute sore throat symptoms in the adult and pediatric patient, except for one on the efficacy of benzydamine in preventing post-operative sore throat, for which it was 67%.
Because all relevant publications on benzydamine are dated and there are no recommendations on its use for the symptomatic treatment of sore throat in European guidelines, this Delphi-based international consensus may be important in reinforcing the appropriate use and effect of benzydamine in the treatment of sore throat among health care professionals.
The authors developed a Delphi questionnaire organized into 15 statements focused on 4 topics: the mechanism of action of benzydamine, the benzydamine treatment in an adult patient and in a pediatric patient, and the advantages of benzydamine over other topical treatments. The survey was administered to a panel of to 320 participants including general practitioners, pediatricians, and pharmacists from 6 European countries (Italy, Germany, Portugal, Romania, Russia, and Spain), who rated their level of agreement or disagreement with each statement on a 6-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with each statement.
Panelists\' agreement on statements was very high. Consensus was reached for all 15 statements in the Delphi survey, with more than 98% positive agreement on topic 4, suggesting a shared view among European healthcare professionals (HCPs) about the advantages of benzydamine over other topical treatments. A strong consensus (> 99%) was reached for all the statements of topic 1 regarding the mechanism of action of benzydamine, except for its anesthetic properties (79%). Strong agreement was reached for all statements in topics 2 and 3 regarding the treatment of acute sore throat symptoms in the adult and pediatric patient, except for one on the efficacy of benzydamine in preventing post-operative sore throat, for which it was 67%.
Because all relevant publications on benzydamine are dated and there are no recommendations on its use for the symptomatic treatment of sore throat in European guidelines, this Delphi-based international consensus may be important in reinforcing the appropriate use and effect of benzydamine in the treatment of sore throat among health care professionals.
摘要：
盐酸苄达明是一种局部作用的非甾体抗炎药（NSAID），具有局部麻醉和镇痛特性，用于缓解急性喉咙痛的症状。这项研究的目的是在药剂师中获得欧洲共识，全科医生和儿科医生对使用盐酸苄达明治疗咽喉肿痛进行了适当的探讨。
作者开发了一份德尔菲问卷，分为15份陈述，重点关注4个主题：苄达明的作用机制，苄达明在成人患者和儿科患者中的治疗，以及苄达明相对于其他局部治疗的优势。这项调查是对包括全科医生在内的320名参与者进行的，儿科医生,和来自6个欧洲国家的药剂师(意大利，德国,葡萄牙,罗马尼亚,俄罗斯,和西班牙），他们以6分的李克特量表对每个陈述的同意或分歧程度进行了评级。共识被预先定义为超过66％的小组同意/不同意每个声明。
小组成员对声明的共识非常高。德尔福调查中的所有15项声明都达成了共识，在主题4上有超过98％的积极同意，这表明欧洲医疗保健专业人员（HCPs）对苄达明相对于其他局部治疗的优势有共同的看法。关于苄达明作用机制的主题1的所有陈述都达成了强烈共识（>99％），除了其麻醉特性（79％）。关于成人和儿科患者急性咽喉痛症状治疗的主题2和3中的所有声明达成了强有力的协议，除了关于苄达明预防术后咽喉痛的功效外，这是67%。
因为所有关于苄达明的相关出版物都是过时的，并且在欧洲指南中没有关于将其用于喉咙痛的对症治疗的建议，这项基于Delphi的国际共识对于加强医疗保健专业人员在咽喉痛治疗中的适当使用苄达明及其效果可能很重要.
作者开发了一份德尔菲问卷，分为15份陈述，重点关注4个主题：苄达明的作用机制，苄达明在成人患者和儿科患者中的治疗，以及苄达明相对于其他局部治疗的优势。这项调查是对包括全科医生在内的320名参与者进行的，儿科医生,和来自6个欧洲国家的药剂师(意大利，德国,葡萄牙,罗马尼亚,俄罗斯,和西班牙），他们以6分的李克特量表对每个陈述的同意或分歧程度进行了评级。共识被预先定义为超过66％的小组同意/不同意每个声明。
小组成员对声明的共识非常高。德尔福调查中的所有15项声明都达成了共识，在主题4上有超过98％的积极同意，这表明欧洲医疗保健专业人员（HCPs）对苄达明相对于其他局部治疗的优势有共同的看法。关于苄达明作用机制的主题1的所有陈述都达成了强烈共识（>99％），除了其麻醉特性（79％）。关于成人和儿科患者急性咽喉痛症状治疗的主题2和3中的所有声明达成了强有力的协议，除了关于苄达明预防术后咽喉痛的功效外，这是67%。
因为所有关于苄达明的相关出版物都是过时的，并且在欧洲指南中没有关于将其用于喉咙痛的对症治疗的建议，这项基于Delphi的国际共识对于加强医疗保健专业人员在咽喉痛治疗中的适当使用苄达明及其效果可能很重要.
